Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Alicia Okines

Showing results (31-40 of 40) with videos related to

Pageof 4
Sort By:
You have reached the last page of results.This site can display upto 40 results.
Breast (Edinburgh, Scotland)|June 29, 2026
Tucatinib in patients with HER2-positive advanced/metastatic breast cancer: A systematic literature review of real-world evidenceRodrigo Sanchez-Bayona, Carey Anders, Rupert Bartsch, et al.
British Journal of Cancer|April 24, 2024
Real world study of sacituzumab govitecan in metastatic triple-negative breast cancer in the United KingdomDaire Hanna, Sophie Merrick, Aruni Ghose, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|May 30, 2020
Intracranial Efficacy and Survival With Tucatinib Plus Trastuzumab and Capecitabine for Previously Treated HER2-Positive Breast Cancer With Brain Metastases in the HER2CLIMB TrialNancy U Lin, Virginia Borges, Carey Anders, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|September 26, 2023
Tucatinib and Trastuzumab for Previously Treated Human Epidermal Growth Factor Receptor 2-Positive Metastatic Biliary Tract Cancer (SGNTUC-019): A Phase II Basket StudyYoshiaki Nakamura, Nobumasa Mizuno, Yu Sunakawa, et al.
The New England Journal of Medicine|December 12, 2019
Tucatinib, Trastuzumab, and Capecitabine for HER2-Positive Metastatic Breast CancerRashmi K Murthy, Sherene Loi, Alicia Okines, et al.
Gut|November 17, 2020
EGFR amplification and outcome in a randomised phase III trial of chemotherapy alone or chemotherapy plus panitumumab for advanced gastro-oesophageal cancersElizabeth C Smyth, Georgios Vlachogiannis, Somaieh Hedayat, et al.
Nature Cancer|February 5, 2022
Functional antibody and T cell immunity following SARS-CoV-2 infection, including by variants of concern, in patients with cancer: the CAPTURE studyAnnika Fendler, Lewis Au, Scott T C Shepherd, et al.
Research Square|September 28, 2021
Functional antibody and T-cell immunity following SARS-CoV-2 infection, including by variants of concern, in patients with cancer: the CAPTURE studyAnnika Fendler, Lewis Au, Scott T C Shepherd, et al.
Nature Cancer|December 24, 2021
Adaptive immunity and neutralizing antibodies against SARS-CoV-2 variants of concern following vaccination in patients with cancer: The CAPTURE studyAnnika Fendler, Scott T C Shepherd, Lewis Au, et al.
Nature Cancer|February 5, 2022
Adaptive immunity and neutralizing antibodies against SARS-CoV-2 variants of concern following vaccination in patients with cancer: the CAPTURE studyAnnika Fendler, Scott T C Shepherd, Lewis Au, et al.
Pageof 4

Showing results (31-40 of 40) with videos related to

Sort By:
Pageof 4
You have reached the last page of results.This site can display upto 40 results.
Breast (Edinburgh, Scotland)|June 29, 2026
Tucatinib in patients with HER2-positive advanced/metastatic breast cancer: A systematic literature review of real-world evidenceRodrigo Sanchez-Bayona, Carey Anders, Rupert Bartsch, et al.
British Journal of Cancer|April 24, 2024
Real world study of sacituzumab govitecan in metastatic triple-negative breast cancer in the United KingdomDaire Hanna, Sophie Merrick, Aruni Ghose, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|May 30, 2020
Intracranial Efficacy and Survival With Tucatinib Plus Trastuzumab and Capecitabine for Previously Treated HER2-Positive Breast Cancer With Brain Metastases in the HER2CLIMB TrialNancy U Lin, Virginia Borges, Carey Anders, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|September 26, 2023
Tucatinib and Trastuzumab for Previously Treated Human Epidermal Growth Factor Receptor 2-Positive Metastatic Biliary Tract Cancer (SGNTUC-019): A Phase II Basket StudyYoshiaki Nakamura, Nobumasa Mizuno, Yu Sunakawa, et al.
The New England Journal of Medicine|December 12, 2019
Tucatinib, Trastuzumab, and Capecitabine for HER2-Positive Metastatic Breast CancerRashmi K Murthy, Sherene Loi, Alicia Okines, et al.
Gut|November 17, 2020
EGFR amplification and outcome in a randomised phase III trial of chemotherapy alone or chemotherapy plus panitumumab for advanced gastro-oesophageal cancersElizabeth C Smyth, Georgios Vlachogiannis, Somaieh Hedayat, et al.
Nature Cancer|February 5, 2022
Functional antibody and T cell immunity following SARS-CoV-2 infection, including by variants of concern, in patients with cancer: the CAPTURE studyAnnika Fendler, Lewis Au, Scott T C Shepherd, et al.
Research Square|September 28, 2021
Functional antibody and T-cell immunity following SARS-CoV-2 infection, including by variants of concern, in patients with cancer: the CAPTURE studyAnnika Fendler, Lewis Au, Scott T C Shepherd, et al.
Nature Cancer|December 24, 2021
Adaptive immunity and neutralizing antibodies against SARS-CoV-2 variants of concern following vaccination in patients with cancer: The CAPTURE studyAnnika Fendler, Scott T C Shepherd, Lewis Au, et al.
Nature Cancer|February 5, 2022
Adaptive immunity and neutralizing antibodies against SARS-CoV-2 variants of concern following vaccination in patients with cancer: the CAPTURE studyAnnika Fendler, Scott T C Shepherd, Lewis Au, et al.
Pageof 4